Read more about Health News Roundup: More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning; Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs and more on Devdiscourse
Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus. In three separate lawsuits in Florida federal court, Novo Nordisk sought orders barring TruLife Pharmacy, Brooksville Pharmaceuticals and WellHealth Inc from selling the products, and seeking unspecified money damages.
Novo Nordisk A/S (NYSE: NVO) has reportedly filed lawsuits against TruLife Pharmacy, Brooksville Pharmaceuticals, and WellHealth Inc in Florida federal court, accusing the pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in Novo Nordisk's weight loss and diabetes drugs. Wegovy is an FDA-approved weight-loss drug, while Ozempic and Rybelsus are approved for diabetes treatment. The FDA warned about the safety risks of using compounded or custom-made v
Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in weight loss and diabetes drugs Wegovy, Ozempic, and Rybelsus.